SK17452000A3 - Kompozície obsahujúce organické mono- alebo dinitráty na liečenie impotencie - Google Patents

Kompozície obsahujúce organické mono- alebo dinitráty na liečenie impotencie Download PDF

Info

Publication number: SK17452000A3
Authority: SK; Slovakia
Prior art keywords: dinitrate; nitrate; composition; mono; topical
Prior art date: 1998-05-18

Application number

SK1745-2000A

Other languages

English (en)

Slovak (sk)

Inventor

Sami Selim

Robert Testman

Ho-Leung Fung

John A. Bauer

Original Assignee

Baker Norton Pharmaceuticals, Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-05-18

Filing date

1999-05-18

Publication date

2001-08-06

1999-05-18 Application filed by Baker Norton Pharmaceuticals, Inc. filed Critical Baker Norton Pharmaceuticals, Inc.

2001-08-06 Publication of SK17452000A3 publication Critical patent/SK17452000A3/sk

Links

239000000203 mixture Substances 0.000 title claims abstract description 40
201000001881 impotence Diseases 0.000 title claims abstract description 21
210000003899 penis Anatomy 0.000 claims abstract description 37
238000000034 method Methods 0.000 claims abstract description 28
230000000699 topical effect Effects 0.000 claims abstract description 21
208000010228 Erectile Dysfunction Diseases 0.000 claims abstract description 8
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 4
229910002651 NO3 Inorganic materials 0.000 claims description 25
NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims description 18
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 17
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 9
238000011200 topical administration Methods 0.000 claims description 9
239000007926 intracavernous injection Substances 0.000 claims description 6
230000008569 process Effects 0.000 claims description 5
NTHGIYFSMNNHSC-UHFFFAOYSA-N 3-methylbutyl nitrate Chemical compound CC(C)CCO[N+]([O-])=O NTHGIYFSMNNHSC-UHFFFAOYSA-N 0.000 claims description 4
241000282414 Homo sapiens Species 0.000 claims description 4
239000003085 diluting agent Substances 0.000 claims description 4
239000002904 solvent Substances 0.000 claims description 4
239000012049 topical pharmaceutical composition Substances 0.000 claims description 4
LNNXFUZKZLXPOF-UHFFFAOYSA-N 2-methylpropyl nitrate Chemical compound CC(C)CO[N+]([O-])=O LNNXFUZKZLXPOF-UHFFFAOYSA-N 0.000 claims description 3
DDBCVXXAMXPHKF-UHFFFAOYSA-N cyclopentyl nitrate Chemical compound [O-][N+](=O)OC1CCCC1 DDBCVXXAMXPHKF-UHFFFAOYSA-N 0.000 claims description 3
239000003125 aqueous solvent Substances 0.000 claims description 2
YJGBGWFCCCQXIM-UHFFFAOYSA-N 2,2-dimethylpropyl nitrate Chemical compound CC(C)(C)CO[N+]([O-])=O YJGBGWFCCCQXIM-UHFFFAOYSA-N 0.000 claims 2
BQJMULPFAUGVGY-UHFFFAOYSA-N 6-nitrooxyhexyl nitrate Chemical compound [O-][N+](=O)OCCCCCCO[N+]([O-])=O BQJMULPFAUGVGY-UHFFFAOYSA-N 0.000 claims 1
150000001875 compounds Chemical class 0.000 abstract description 15
238000011282 treatment Methods 0.000 abstract description 8
SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 37
239000000006 Nitroglycerin Substances 0.000 description 37
229960003711 glyceryl trinitrate Drugs 0.000 description 37
230000000694 effects Effects 0.000 description 18
241000700159 Rattus Species 0.000 description 16
239000003814 drug Substances 0.000 description 14
230000009885 systemic effect Effects 0.000 description 14
229940079593 drug Drugs 0.000 description 12
230000004872 arterial blood pressure Effects 0.000 description 11
239000000243 solution Substances 0.000 description 11
230000036772 blood pressure Effects 0.000 description 10
230000004044 response Effects 0.000 description 10
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
239000007924 injection Substances 0.000 description 8
238000002347 injection Methods 0.000 description 8
239000002674 ointment Substances 0.000 description 8
XQYZDYMELSJDRZ-UHFFFAOYSA-N papaverine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 XQYZDYMELSJDRZ-UHFFFAOYSA-N 0.000 description 8
210000001519 tissue Anatomy 0.000 description 8
241001465754 Metazoa Species 0.000 description 7
150000002823 nitrates Chemical class 0.000 description 7
238000010998 test method Methods 0.000 description 7
230000002792 vascular Effects 0.000 description 7
241000700199 Cavia porcellus Species 0.000 description 6
XRKMNJXYOFSTBE-UHFFFAOYSA-N disodium;iron(4+);nitroxyl anion;pentacyanide;dihydrate Chemical compound O.O.[Na+].[Na+].[Fe+4].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].O=[N-] XRKMNJXYOFSTBE-UHFFFAOYSA-N 0.000 description 6
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
229940082615 organic nitrates used in cardiac disease Drugs 0.000 description 6
238000002360 preparation method Methods 0.000 description 6
SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 6
229940083618 sodium nitroprusside Drugs 0.000 description 6
231100000673 dose–response relationship Toxicity 0.000 description 5
230000001965 increasing effect Effects 0.000 description 5
230000035515 penetration Effects 0.000 description 5
235000019271 petrolatum Nutrition 0.000 description 5
238000012360 testing method Methods 0.000 description 5
230000024883 vasodilation Effects 0.000 description 5
229940124549 vasodilator Drugs 0.000 description 5
239000003071 vasodilator agent Substances 0.000 description 5
210000003462 vein Anatomy 0.000 description 5
229930008281 A03AD01 - Papaverine Natural products 0.000 description 4
239000008280 blood Substances 0.000 description 4
210000004369 blood Anatomy 0.000 description 4
230000017531 blood circulation Effects 0.000 description 4
230000036765 blood level Effects 0.000 description 4
239000000969 carrier Substances 0.000 description 4
230000002500 effect on skin Effects 0.000 description 4
238000009472 formulation Methods 0.000 description 4
239000000499 gel Substances 0.000 description 4
229960001789 papaverine Drugs 0.000 description 4
229940068196 placebo Drugs 0.000 description 4
239000000902 placebo Substances 0.000 description 4
230000009467 reduction Effects 0.000 description 4
230000001225 therapeutic effect Effects 0.000 description 4
239000003981 vehicle Substances 0.000 description 4
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
206010019233 Headaches Diseases 0.000 description 3
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
239000004264 Petrolatum Substances 0.000 description 3
230000002411 adverse Effects 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
239000006071 cream Substances 0.000 description 3
231100000869 headache Toxicity 0.000 description 3
239000007788 liquid Substances 0.000 description 3
150000002826 nitrites Chemical class 0.000 description 3
229940066842 petrolatum Drugs 0.000 description 3
229910001961 silver nitrate Inorganic materials 0.000 description 3
230000000304 vasodilatating effect Effects 0.000 description 3
GMVPRGQOIOIIMI-UHFFFAOYSA-N (8R,11R,12R,13E,15S)-11,15-Dihydroxy-9-oxo-13-prostenoic acid Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CCCCCCC(O)=O GMVPRGQOIOIIMI-UHFFFAOYSA-N 0.000 description 2
GCKMFJBGXUYNAG-UHFFFAOYSA-N 17alpha-methyltestosterone Natural products C1CC2=CC(=O)CCC2(C)C2C1C1CCC(C)(O)C1(C)CC2 GCKMFJBGXUYNAG-UHFFFAOYSA-N 0.000 description 2
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
241000700198 Cavia Species 0.000 description 2
GCKMFJBGXUYNAG-HLXURNFRSA-N Methyltestosterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)CC2 GCKMFJBGXUYNAG-HLXURNFRSA-N 0.000 description 2
MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
206010047141 Vasodilatation Diseases 0.000 description 2
229960000711 alprostadil Drugs 0.000 description 2
239000003048 aphrodisiac agent Substances 0.000 description 2
230000002509 aphrodisiac effect Effects 0.000 description 2
230000008901 benefit Effects 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
239000001273 butane Substances 0.000 description 2
WERYXYBDKMZEQL-UHFFFAOYSA-N butane-1,4-diol Chemical compound OCCCCO WERYXYBDKMZEQL-UHFFFAOYSA-N 0.000 description 2
230000008859 change Effects 0.000 description 2
230000008030 elimination Effects 0.000 description 2
238000003379 elimination reaction Methods 0.000 description 2
239000003623 enhancer Substances 0.000 description 2
230000001856 erectile effect Effects 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
210000003608 fece Anatomy 0.000 description 2
210000001105 femoral artery Anatomy 0.000 description 2
210000003953 foreskin Anatomy 0.000 description 2
238000011597 hartley guinea pig Methods 0.000 description 2
LLEVMYXEJUDBTA-UHFFFAOYSA-N heptanedinitrile Chemical compound N#CCCCCCC#N LLEVMYXEJUDBTA-UHFFFAOYSA-N 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
239000008274 jelly Substances 0.000 description 2
239000006210 lotion Substances 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
238000005259 measurement Methods 0.000 description 2
230000004060 metabolic process Effects 0.000 description 2
239000002207 metabolite Substances 0.000 description 2
229960001566 methyltestosterone Drugs 0.000 description 2
125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
230000001737 promoting effect Effects 0.000 description 2
GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 description 2
XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 2
239000011541 reaction mixture Substances 0.000 description 2
239000007921 spray Substances 0.000 description 2
238000003756 stirring Methods 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
150000003515 testosterones Chemical class 0.000 description 2
229940124597 therapeutic agent Drugs 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
231100000331 toxic Toxicity 0.000 description 2
230000002588 toxic effect Effects 0.000 description 2
210000002700 urine Anatomy 0.000 description 2
230000002227 vasoactive effect Effects 0.000 description 2
ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
ZNQVEEAIQZEUHB-UHFFFAOYSA-N 2-ethoxyethanol Chemical compound CCOCCO ZNQVEEAIQZEUHB-UHFFFAOYSA-N 0.000 description 1
229940093475 2-ethoxyethanol Drugs 0.000 description 1
BKOOMYPCSUNDGP-UHFFFAOYSA-N 2-methylbut-2-ene Chemical compound CC=C(C)C BKOOMYPCSUNDGP-UHFFFAOYSA-N 0.000 description 1
USEGQJLHQSTGHW-UHFFFAOYSA-N 3-bromo-2-methylprop-1-ene Chemical compound CC(=C)CBr USEGQJLHQSTGHW-UHFFFAOYSA-N 0.000 description 1
HBTAOSGHCXUEKI-UHFFFAOYSA-N 4-chloro-n,n-dimethyl-3-nitrobenzenesulfonamide Chemical compound CN(C)S(=O)(=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 HBTAOSGHCXUEKI-UHFFFAOYSA-N 0.000 description 1
206010002383 Angina Pectoris Diseases 0.000 description 1
241000282412 Homo Species 0.000 description 1
208000029549 Muscle injury Diseases 0.000 description 1
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
QMGVPVSNSZLJIA-UHFFFAOYSA-N Nux Vomica Natural products C1C2C3C4N(C=5C6=CC=CC=5)C(=O)CC3OCC=C2CN2C1C46CC2 QMGVPVSNSZLJIA-UHFFFAOYSA-N 0.000 description 1
244000131316 Panax pseudoginseng Species 0.000 description 1
235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
235000003140 Panax quinquefolius Nutrition 0.000 description 1
206010033892 Paraplegia Diseases 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
ALQSHHUCVQOPAS-UHFFFAOYSA-N Pentane-1,5-diol Chemical compound OCCCCCO ALQSHHUCVQOPAS-UHFFFAOYSA-N 0.000 description 1
229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
239000004147 Sorbitan trioleate Substances 0.000 description 1
PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
239000000654 additive Substances 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
238000010171 animal model Methods 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
230000008321 arterial blood flow Effects 0.000 description 1
210000001367 artery Anatomy 0.000 description 1
229940125717 barbiturate Drugs 0.000 description 1
HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 description 1
229910052788 barium Inorganic materials 0.000 description 1
DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
235000019445 benzyl alcohol Nutrition 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
238000012754 cardiac puncture Methods 0.000 description 1
239000004359 castor oil Substances 0.000 description 1
235000019438 castor oil Nutrition 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
239000003086 colorant Substances 0.000 description 1
230000001609 comparable effect Effects 0.000 description 1
239000003433 contraceptive agent Substances 0.000 description 1
230000002254 contraceptive effect Effects 0.000 description 1
239000002285 corn oil Substances 0.000 description 1
235000005687 corn oil Nutrition 0.000 description 1
-1 cyclopentyl- O - Chemical class 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
230000035487 diastolic blood pressure Effects 0.000 description 1
XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 1
229940031578 diisopropyl adipate Drugs 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
230000009977 dual effect Effects 0.000 description 1
230000004064 dysfunction Effects 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
210000005225 erectile tissue Anatomy 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
239000012467 final product Substances 0.000 description 1
238000004508 fractional distillation Methods 0.000 description 1
235000008434 ginseng Nutrition 0.000 description 1
229960005150 glycerol Drugs 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
239000007943 implant Substances 0.000 description 1
238000002513 implantation Methods 0.000 description 1
239000005414 inactive ingredient Substances 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
208000014674 injury Diseases 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
230000000622 irritating effect Effects 0.000 description 1
230000007794 irritation Effects 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
235000015110 jellies Nutrition 0.000 description 1
239000004816 latex Substances 0.000 description 1
229920000126 latex Polymers 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
229960002006 linsidomine Drugs 0.000 description 1
FKDHHVKWGRFRTG-UHFFFAOYSA-N linsidomine Chemical compound [N-]1OC(=N)C=[N+]1N1CCOCC1 FKDHHVKWGRFRTG-UHFFFAOYSA-N 0.000 description 1
239000002960 lipid emulsion Substances 0.000 description 1
238000013332 literature search Methods 0.000 description 1
230000007774 longterm Effects 0.000 description 1
238000007726 management method Methods 0.000 description 1
238000004949 mass spectrometry Methods 0.000 description 1
239000000463 material Substances 0.000 description 1
210000002464 muscle smooth vascular Anatomy 0.000 description 1
210000005036 nerve Anatomy 0.000 description 1
150000002825 nitriles Chemical class 0.000 description 1
FBUKVWPVBMHYJY-UHFFFAOYSA-N nonanoic acid Chemical compound CCCCCCCCC(O)=O FBUKVWPVBMHYJY-UHFFFAOYSA-N 0.000 description 1
230000008816 organ damage Effects 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
235000019809 paraffin wax Nutrition 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
230000018052 penile erection Effects 0.000 description 1
230000002085 persistent effect Effects 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
MRBDMNSDAVCSSF-UHFFFAOYSA-N phentolamine Chemical compound C1=CC(C)=CC=C1N(C=1C=C(O)C=CC=1)CC1=NCCN1 MRBDMNSDAVCSSF-UHFFFAOYSA-N 0.000 description 1
229960001999 phentolamine Drugs 0.000 description 1
SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 1
229960001802 phenylephrine Drugs 0.000 description 1
239000000419 plant extract Substances 0.000 description 1
239000004014 plasticizer Substances 0.000 description 1
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
229940068968 polysorbate 80 Drugs 0.000 description 1
229920000053 polysorbate 80 Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
229940069328 povidone Drugs 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
201000011264 priapism Diseases 0.000 description 1
239000000047 product Substances 0.000 description 1
238000011552 rat model Methods 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
230000004648 relaxation of smooth muscle Effects 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
208000018316 severe headache Diseases 0.000 description 1
230000001568 sexual effect Effects 0.000 description 1
230000036332 sexual response Effects 0.000 description 1
210000002460 smooth muscle Anatomy 0.000 description 1
239000000050 smooth muscle relaxant Substances 0.000 description 1
239000011734 sodium Substances 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
229910052938 sodium sulfate Inorganic materials 0.000 description 1
235000011152 sodium sulphate Nutrition 0.000 description 1
239000001593 sorbitan monooleate Substances 0.000 description 1
235000011069 sorbitan monooleate Nutrition 0.000 description 1
229940035049 sorbitan monooleate Drugs 0.000 description 1
229960000391 sorbitan trioleate Drugs 0.000 description 1
235000019337 sorbitan trioleate Nutrition 0.000 description 1
230000021595 spermatogenesis Effects 0.000 description 1
238000012453 sprague-dawley rat model Methods 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
238000007910 systemic administration Methods 0.000 description 1
229960003604 testosterone Drugs 0.000 description 1
IDELNEDBPWKHGK-UHFFFAOYSA-N thiobutabarbital Chemical compound CCC(C)C1(CC)C(=O)NC(=S)NC1=O IDELNEDBPWKHGK-UHFFFAOYSA-N 0.000 description 1
238000013271 transdermal drug delivery Methods 0.000 description 1
230000008733 trauma Effects 0.000 description 1
230000000472 traumatic effect Effects 0.000 description 1
150000003626 triacylglycerols Chemical class 0.000 description 1
230000000982 vasogenic effect Effects 0.000 description 1
239000003039 volatile agent Substances 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1
239000003871 white petrolatum Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/04—Nitro compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Reproductive Health (AREA)
Gynecology & Obstetrics (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Endocrinology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Urology & Nephrology (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Plant Substances (AREA)
Orthopedics, Nursing, And Contraception (AREA)

SK1745-2000A 1998-05-18 1999-05-18 Kompozície obsahujúce organické mono- alebo dinitráty na liečenie impotencie SK17452000A3 (sk)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US09/081,108 US6056966A (en)	1998-05-18	1998-05-18	Method and compositions for treating impotence
PCT/US1999/010933 WO1999059575A1 (en)	1998-05-18	1999-05-18	Compositions comprising organic mono- or dinitrate for treating impotence

Publications (1)

Publication Number	Publication Date
SK17452000A3 true SK17452000A3 (sk)	2001-08-06

Family

ID=22162141

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK1745-2000A SK17452000A3 (sk)	1998-05-18	1999-05-18	Kompozície obsahujúce organické mono- alebo dinitráty na liečenie impotencie

Country Status (17)

Country	Link
US (1)	US6056966A (no)
EP (1)	EP1079823A1 (no)
JP (1)	JP2003511343A (no)
KR (1)	KR20010071283A (no)
CN (1)	CN1307472A (no)
AR (1)	AR018861A1 (no)
AU (1)	AU758035B2 (no)
BR (1)	BR9911060A (no)
CA (1)	CA2332328A1 (no)
CO (1)	CO5050298A1 (no)
HU (1)	HUP0101668A2 (no)
IL (1)	IL139751A0 (no)
NO (1)	NO20005793L (no)
PL (1)	PL344335A1 (no)
SK (1)	SK17452000A3 (no)
WO (1)	WO1999059575A1 (no)
ZA (1)	ZA200006733B (no)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2002007757A2 (en)	2000-07-21	2002-01-31	Lue Tom F	Prevention and treatment of sexual arousal disorders
US7223406B2 (en)	2000-07-21	2007-05-29	The Regents Of The University Of California	Methods and compositions for preventing and treating male erectile dysfunction and female sexual arousal disorder
EP1472021A4 (en) *	2002-01-11	2008-04-16	David R Whitlock	AMMONIA OXIDIZING BACTERIUM COMPOSITIONS AND METHODS OF USE
US20030219696A1 (en) *	2002-05-23	2003-11-27	Moreland Gerald W.	Method and apparatus for preventing backflow in dental saliva evacuators
US20070148136A1 (en) *	2003-09-26	2007-06-28	Whitlock David R	Methods of using ammonia oxidizing bacteria
US7507842B2 (en)	2005-08-12	2009-03-24	Radiorx, Inc.	Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof
US20070135380A1 (en) *	2005-08-12	2007-06-14	Radiorx, Inc.	O-nitro compounds, pharmaceutical compositions thereof and uses thereof
US20070175484A1 (en) *	2006-01-30	2007-08-02	Staab Robert J	Condoms for beneficial agents delivery
US8212735B2 (en) *	2009-06-05	2012-07-03	Nokia Corporation	Near field communication
WO2011057386A1 (en) *	2009-11-13	2011-05-19	Oral Delivery Technology Ltd.	Composition and prophylactic device for enhancing sexual performance or pleasure
US9023890B2 (en) *	2009-12-02	2015-05-05	The Charlotte-Mecklenburg Hospital Authority	Nitrate esters and their use for the treatment of muscle and muscle related diseases
US8471041B2 (en) *	2010-02-09	2013-06-25	Alliant Techsystems Inc.	Methods of synthesizing and isolating N-(bromoacetyl)-3,3-dinitroazetidine and a composition including the same
US9452117B2 (en)	2011-06-01	2016-09-27	The Charlotte-Mecklenburg Hospital Authority	Nitrate esters and their use for the treatment of muscle and muscle related diseases
US8664247B2 (en)	2011-08-26	2014-03-04	Radiorx, Inc.	Acyclic organonitro compounds for use in treating cancer
US20140308260A1 (en)	2011-10-07	2014-10-16	Radiorx, Inc.	Methods and compositions comprising a nitrite-reductase promoter for treatment of medical disorders and preservation of blood products
JP6019126B2 (ja)	2011-10-07	2016-11-02	エピセントアーレックス・インコーポレイテッドＥｐｉｃｅｎｔＲｘ，Ｉｎｃ．	有機ニトロチオエーテル化合物およびその医療用途
CN104352436A (zh) *	2014-10-09	2015-02-18	南京泽恒医药技术开发有限公司	一种硝酸甘油原位成形凝胶喷雾剂及其制备方法
US10342778B1 (en)	2015-10-20	2019-07-09	Epicentrx, Inc.	Treatment of brain metastases using organonitro compound combination therapy
US9987270B1 (en)	2015-10-29	2018-06-05	Epicentrix, Inc.	Treatment of gliomas using organonitro compound combination therapy
SG11201805942UA (en)	2016-01-11	2018-08-30	Epicentrx Inc	Compositions and methods for intravenous administration of 2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanone
EA201990949A1 (ru)	2016-10-14	2019-10-31		Сульфоксиалкильные органические нитросоединения и родственные соединения и фармацевтические композиции для применения в медицине
KR102869384B1 (ko)	2017-07-07	2025-10-15	에피센트알엑스, 인코포레이티드	치료제의 비경구 투여를 위한 조성물
WO2019164593A2 (en)	2018-01-08	2019-08-29	Epicentrx, Inc.	Methods and compositions utilizing rrx-001 combination therapy for radioprotection
RU2757309C1 (ru) *	2020-11-02	2021-10-13	Ассим Абдель Гани Ахмед Сонбол	Композиция для коррекции сексуальной дисфункции у мужчин

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4112115A (en) *	1976-11-08	1978-09-05	Coghlan Charles C	Therapy of leg muscle cramps
US4913469A (en) *	1988-08-08	1990-04-03	Cameron Iron Works Usa, Inc.	Wellhead slip and seal assembly
NL8802276A (nl) *	1988-09-15	1990-04-02	Cedona Pharm Bv	Geneesmiddel met relaxerende werking, dat als aktieve stof een nitraatester bevat.
JPH02200633A (ja) *	1989-01-27	1990-08-08	Akamatsu Shoji Kk	血管拡張剤
US5059603A (en) *	1989-06-12	1991-10-22	Centuries Laboratories, Inc.	Method and composition for treating impotence
US5278192A (en) *	1992-07-02	1994-01-11	The Research Foundation Of State University Of New York	Method of vasodilator therapy for treating a patient with a condition
US5646181A (en) *	1992-07-02	1997-07-08	Research Foundation Of State University Of New York	Method and compositions for treating impotence
EP0689435A1 (de) *	1993-03-15	1996-01-03	Byk Nederland Bv	Verwendung von substituierten alkylnitraten zur behandlung des krankhaft erhöhten augeninnendruckes
CA2215307A1 (en) *	1995-03-14	1996-09-19	Vivus, Incorporated	Pharmaceutical compositions and kits for preventing erectile dysfunction
CA2294480C (en) *	1997-06-23	2008-05-20	Queen's University At Kingston	Microdose therapy of female sexual dysfunction by no, co, and their donors

1998
- 1998-05-18 US US09/081,108 patent/US6056966A/en not_active Expired - Fee Related
1999
- 1999-05-18 EP EP99923179A patent/EP1079823A1/en not_active Withdrawn
- 1999-05-18 PL PL99344335A patent/PL344335A1/xx unknown
- 1999-05-18 CO CO99030405A patent/CO5050298A1/es unknown
- 1999-05-18 AR ARP990102349A patent/AR018861A1/es not_active Application Discontinuation
- 1999-05-18 HU HU0101668A patent/HUP0101668A2/hu unknown
- 1999-05-18 CN CN99807875A patent/CN1307472A/zh active Pending
- 1999-05-18 CA CA002332328A patent/CA2332328A1/en not_active Abandoned
- 1999-05-18 KR KR1020007012921A patent/KR20010071283A/ko not_active Withdrawn
- 1999-05-18 WO PCT/US1999/010933 patent/WO1999059575A1/en not_active Ceased
- 1999-05-18 IL IL13975199A patent/IL139751A0/xx unknown
- 1999-05-18 JP JP2000549240A patent/JP2003511343A/ja active Pending
- 1999-05-18 BR BR9911060-1A patent/BR9911060A/pt not_active IP Right Cessation
- 1999-05-18 SK SK1745-2000A patent/SK17452000A3/sk unknown
- 1999-05-18 AU AU40006/99A patent/AU758035B2/en not_active Ceased
2000
- 2000-11-16 NO NO20005793A patent/NO20005793L/no not_active Application Discontinuation
- 2000-11-17 ZA ZA200006733A patent/ZA200006733B/xx unknown

Also Published As

Publication number	Publication date
AU758035B2 (en)	2003-03-13
CN1307472A (zh)	2001-08-08
IL139751A0 (en)	2002-02-10
PL344335A1 (en)	2001-11-05
US6056966A (en)	2000-05-02
BR9911060A (pt)	2001-02-06
EP1079823A1 (en)	2001-03-07
WO1999059575A1 (en)	1999-11-25
ZA200006733B (en)	2001-09-18
HUP0101668A2 (hu)	2001-10-28
AU4000699A (en)	1999-12-06
JP2003511343A (ja)	2003-03-25
NO20005793D0 (no)	2000-11-16
CO5050298A1 (es)	2001-06-27
AR018861A1 (es)	2001-12-12
CA2332328A1 (en)	1999-11-25
NO20005793L (no)	2001-01-17
KR20010071283A (ko)	2001-07-28

Publication	Publication Date	Title
AU758035B2 (en)	2003-03-13	Compositions comprising organic mono- or dinitrate for treating impotence
AU702338B2 (en)	1999-02-18	Method and compositions for treating impotence
US5059603A (en)	1991-10-22	Method and composition for treating impotence
DE69415535T2 (de)	1999-06-17	Verfahren zur regulierung der sexuellen reaktion beim menschen
SK117597A3 (en)	1998-01-14	Water-based topical cream containing nitroglycerin; method of preparation and use thereof
KR890000183B1 (ko)	1989-03-09	경피 침투가 증진된 생리학적 활성 제제 및 그의 제조방법
HU229083B1 (en)	2013-07-29	Compositions and methods for amelioration of human female sexual dysfunction
US6589990B1 (en)	2003-07-08	Methods and compositions for misoprostol compound treatment of erectile dysfunction
KR20020073498A (ko)	2002-09-26	남성 발기부전증을 치료하기 위한 프로스타글란딘 조성물및 방법
WO1999038472A2 (en)	1999-08-05	Topical vasodilatory gel composition and methods of use and production
US5336678A (en)	1994-08-09	Use of minoxidil for treating erectile impotence
US6365590B1 (en)	2002-04-02	Compounds, compositions and methods for treating erectile dysfunction
JPH07506333A (ja)	1995-07-13	勃起機能不全症治療用ピリジルグアニジン化合物
JP2905210B2 (ja)	1999-06-14	経皮、経粘膜吸収促進剤および経皮、経粘膜製剤
WO2004002444A2 (en)	2004-01-08	A platform for transdermal formulations (ptf)
MXPA00011316A (es)	2001-12-04	Composiciones que contienen mono o dinitrato organico para el tratamiento de la impotencia
CZ20004271A3 (cs)	2001-05-16	Přípravky obsahující organické mononitráty nebo dinitráty vhodné pro léčení impotence
CN1491647A (zh)	2004-04-28	经皮式用于治疗阳痿和女性性冷淡并防治性病的组合物
RU2618462C2 (ru)	2017-05-03	Способ и улучшенная фармацевтическая композиция для ускорения трансдермальной доставки ингибитора pde-5
HU179942B (en)	1983-01-28	Process for preparing injectable pharmaceutical compositions against internal parasites,particularly for the treatment and prevention of rot of sheep
CA2325930A1 (en)	2001-07-29	A medicament for prevention and treatment of sexual dysfunction
US6897239B1 (en)	2005-05-24	Use of misoprostol and/or metabolites of misoprostol for treating sexual dysfunction in women
AU3395999A (en)	1999-08-05	Method and compositions for treating impotence
RU2660353C2 (ru)	2018-07-05	Способ и улучшенная фармацевтическая композиция для ускорения трансдермальной доставки ингибитора pde-5
KR100586422B1 (ko)	2006-06-08	발기부전 치료용 외용제 조성물